オプションチェーンは、Blue Birdの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Blue Birdの市場センチメントを評価します。.

Blue Bird (NASDAQ:BLBD) 株価情報, オプションチェーン

Blue Bird

Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.

Blue Bird Corp

On Saturday, Teva Pharmaceuticals Industries Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug (TEV&#8217;574/SAR447189) for moderate-to-severe ulcerative colitis (UC) and Crohn&#8217;s disease (CD), the two most common forms of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43900182/teva-and-sanofi-present-new-positive-phase-2b-study-results-at-ecco-2025-reinforcing-best-in-class" rel="noreferrer noopener">inflammatory bowel disease (IBD)</a>.
These results were shared at the Congress of the European Crohn&#8217;s and Colitis Organisation.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/02/43601535/axsome-therapeutics-resolves-generic-patent-litigation-with-teva-over-depression-drug-analyst-maintains-axsome-as-top-pick-for-2025" rel="noreferrer noopener">Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As &#8216;Top Pick For 2025&#8217;</a>
Ulcerative colitis
<ul>
<li>In the UC cohort of the RELIEVE UCCD study, 36% (450 mg dose) and 48% (900 mg dose) of patients treated with duvakitug achieved the primary endpoint of clinical remission (mMS) at week 14 compared to 20% treated with placebo.</li>
<li>Placebo-adjusted rates were 16% (450 mg) and 27% (900 mg) (p=0.050 and 0.003, respectively).
<ul>
<li>Higher clinical remission rates were observed for both doses of duvakitug versus placebo in both advanced therapy (AT)-experienced and AT-naïve subgroups of patients.AT-experienced: 29% (450 mg) and 36% (900 mg), with placebo-adjusted rates of 22% (450 mg) and 29% (900 mg).</li>
<li>AT-naïve: 39% (450 mg) and 53% (900 mg), with placebo-adjusted rates of 12% (450 mg) and 26% (900 mg).1-3</li>
</ul>
</li>
</ul>
Crohn&#8217;s disease
<ul>
<li>In the CD cohort of the RELIEVE UCCD study, 26% (450 mg) and 48% (900 mg) of patients with CD treated with duvakitug achieved the primary endpoint of endoscopic response (SES-CD) compared to 13% on placebo.</li>
<li>Placebo-adjusted rates were 13% (450 mg) and 35% (900 mg) at week 14 (p=0.058 and &lt;0.001, respectively).
<ul>
<li>Higher endoscopic response rates were observed for both doses of duvakitug versus placebo in both AT-experienced and -naïve subgroups of patients.AT-experienced: 11% (450 mg) and 48% (900 mg), with placebo-adjusted rates of 7% (450 mg) and 44% (900 mg).</li>
<li>AT-naïve: 47% (450 mg) and 47% (900 mg), with placebo-adjusted rates of 25% (450 mg) and 25% (900 mg).</li>
</ul>
</li>
</ul>
The company expects to start the Phase 3 program in the second half of 2025.
Price Action: TEVA stock is down 0.18% at $16.70, and SNY stock is down 0.48% at $54.20 during the premarket session on last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/02/43901425/apple-bows-out-of-uks-cloud-encryption-amid-governments-backdoor-demands" target="_blank" rel="noreferrer noopener">Apple Bows Out of UK&#8217;s Cloud Encryption Amid Government&#8217;s &#8216;Backdoor&#8217; Demands</a></li>
</ul>
Photo by Ralf Liebhold via Shutterstock

Biotech

Large Cap

News

Health Care

General

TEVA

Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease

Stephens &amp; Co. analyst John Campbell maintains Fidelity National Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) with a Overweight and raises the price target from $68 to $75.

Price Target

Analyst Ratings

Stephens & Co. Maintains Overweight on Fidelity National Finl, Raises Price Target to $75

OPTT

Ocean Power Technologies Announces Successful Demonstration Of Defense And Security Capabilities At NAVDEX. Showcasing WAM-V Unmanned Surface Vehicles, Next Generation Powerbuoy, And AI Capable Merrows

Manulife Financial Corporation ("Manulife") announced today that it has&nbsp;entered into an automatic share repurchase plan (the "automatic plan") under which its designated broker will repurchase Manulife's common shares pursuant to its previously announced normal course issuer bid ("NCIB"). The actual number of common shares purchased under the automatic plan, the timing of such purchases and the price at which common shares are purchased will depend upon future market conditions. The automatic plan, which was pre-cleared by the TSX, provides for the potential repurchase of common shares at any time, including when Manulife ordinarily would not be active in the market due to its own internal trading blackout periods, insider trading rules, or otherwise.

Buybacks

Manulife Initiates Automatic Share Repurchase Plan Under Normal Course Issuer Bid; No Terms Disclosed

Stephens &amp; Co. analyst Sudan Loganathan maintains ADC Therapeutics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>) with a Overweight and raises the price target from $6 to $8.

ADCT

Stephens & Co. Maintains Overweight on ADC Therapeutics, Raises Price Target to $8

Piper Sandler analyst Derek Podhaizer maintains Solaris Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEI#NYSE">SEI</a>) with a Overweight and raises the price target from $37 to $50.

Piper Sandler Maintains Overweight on Solaris Energy, Raises Price Target to $50

On Friday, Co-Diagnostics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CODX#NASDAQ">CODX</a>) withdrew its FDA 510(k) application for its Co-Dx PCR COVID-19 Test on the PCR Pro in favor of submitting an enhanced version of the test <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43895005/co-diagnostics-inc-announces-intention-to-submit-enhanced-version-of-covid-19-test-to-fda-for-510-" rel="noreferrer noopener">for 510(k) clearance</a>.
The company&#8217;s decision to withdraw the submission was based on discussions with the FDA regarding the ability to detect a potential deterioration of one component of the test related to shelf-life stability.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/02/43890231/why-is-cancer-focused-exelixis-stock-trading-higher-on-friday" rel="noreferrer noopener">Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?</a>
Following dialogue with the FDA and exploring the various courses of action available, Co-Dx has determined that the best long-term solution would be to submit an enhanced version of the test to address the matter raised in the 510(k) review process.&nbsp;
After collecting clinical evaluation data to support the new test&#8217;s performance, the company plans to submit the next iteration of the Co-Dx PCR COVID-19 test for 510(k) OTC clearance.
A new submission also allows the company to incorporate more recent&nbsp;Co-Dx PCR platform developments into the COVID-19 test, which Co-Dx believes will help create greater operational and manufacturing efficiencies. For example, it could consolidate manufacturing processes to utilize the next generation of test kits and instruments across all tests on the at-home and point-of-care platform.
The Co-Dx PCR COVID-19 test is expected to be followed by additional tests for tuberculosis, upper-respiratory multiplex, and a multiplex HPV test, among others.
Price Action: CODX stock is down 14.9% at $0.60 during the premarket session on last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/02/43894411/volkswagens-audi-to-grow-north-american-production-report" target="_blank" rel="noreferrer noopener">Volkswagen&#8217;s Audi To Grow North American Production: Report</a></li>
</ul>
Photo by Horth Rasuer via Shutterstock

Penny Stocks

Movers

Trading Ideas

CODX

Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version

The company's board of directors also authorized an additional share repurchase program of $1.5 billion of the company's common stock. The authorization is effective immediately and is additive to the previous $1.5 billion program authorized on November 3, 2023, which had $194 million remaining authorized and available for repurchase on December 31, 2024.
Since 2017, the company has repurchased $6.7 billion of its common stock, representing 41 percent of its outstanding shares, and has paid cash dividends of $1.7 billion through December 31, 2024. In the last five years, the company continued its meaningful strategic growth, investing $7.1 billion in capital investments and acquisitions, while maintaining a best-in-class, after-tax-return-on-invested capital of 24 percent.&nbsp;

STLD

Steel Dynamics Authorizes An Additional Share Repurchase Program Of $1.5B Of The Company's Common Stock

BACK

Ignite Proteomics, Subsidiary Of IMAC Holdings, Announces MHC-II Expression As Superior Predictor For Pembrolizumab Response Compared To PD-L1 Ahead Of NCCN Conference

Wolfe Research analyst Nigel Coe upgrades Carrier Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CARR#NYSE">CARR</a>) from Peer Perform to Outperform and maintains the price target from $80 to $80.

Upgrades

CARR

Wolfe Research Upgrades Carrier Global to Outperform, Maintains Price Target to $80

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/24103358/AAC.jpeg" alt="" class="wp-image-6312" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/24103358/AAC.jpeg 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/24103358/AAC-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/24103358/AAC-768x512.jpeg 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
Surging smartphone sales helped to power the acoustic component supplier to turbocharged profit growth last year, but the stock failed to rally strongly on the news

<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>AAC Technologies said it expects to report that its profit rose as much as 145% last year</li>
<li>The acoustic component maker said car acoustics are expected to become a future growth driver</li>
</ul>
Talk about big noises falling on deaf ears.
On Feb. 13, acoustic component supplier AAC Technologies Holdings Inc. (2018.HK) made <a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0213/2025021300995.pdf">an announcement</a> that should have been music to investor ears, saying after the market closed it would report that its profit more than doubled last year. The next day, which just happened to be Valentine's Day, brokerage UOB Kay Hian sharply raised its target price for the company to HK$48 from HK$38.10, while maintain its "hold" rating.
While the benchmark Hang Seng Composite Index logged an impressive 805-point Valentine's Day jump that day, AAC's shares attracted less love from investors, rising by a relatively modest 3% to close at exactly HK$48. The stock is up 45% over the last six months, amid a broader rally that has seen the Hang Seng Technology Index rise by an even bigger 70% over that time. But the muted response to the positive profit alert could show AAC's own rally may be running out of steam at around the HK$50 level.
Having made it to UOB Kay Hian's new target price, the new question for AAC now becomes whether there's room for any future upside, or if the stock may have peaked for now.
<h4 class="wp-block-heading">The $26-billion company</h4>
AAC Technologies once used its cutting-edge acoustic technology to win over major clients, including the likes of Apple. The company rode the smartphone boom for most of the 2010s to become a constituent stock of Hong Kong's Hang Seng Index, as its market capitalization peaked as high as HK$205.3 billion ($26.4 billion) in 2017.
But smartphone saturation and growing competition finally caught up with AAC, sending it into a downward spiral. Its shares lost more than 90% of their value, sending its market value to less than HK$13 billion at its low. Following several years at rock bottom, the company has finally begun to find its way past this darker period in its history.
According to its pre-Valentine's Day announcement, AAC expects to report a 2024 profit of between 1.7 billion yuan ($234 million) and 1.82 billion yuan, up 130% to 145% year-on-year. It attributed the rebound to a recovering global smartphone market and its own improved operations. It also completed its acquisition of Acoustics Solutions International B.V., a supplier of acoustic components and audio systems, during the year, providing a booster to its automotive business.
<h4 class="wp-block-heading">Big share gains</h4>
The big profit jump adds to previous signals that AAC's comeback isn't just a fluke. The company's profit actually grew by an even larger 257% year-on-year in the first half of 2024 to 537 million yuan. Calculations using the latest profit forecast show the company's profit was at least 1.16 billion yuan in the second half of the year, more than double the first-half profit, showing the business continued gaining momentum in the final six months of 2024.
In fact, AAC Technologies' share price has already risen strongly as its comeback gains steam, up 180% over the past year.
But is there further room for even greater gains? Let's explore that question further. After all, the company once had revenue as high as 21.1 billion yuan, and a net profit of 5.33 billion yuan at its peak in 2017. Thus, while the 2024 profit is up sharply from 2023, it's still a far cry from the company's historic highs.
<h4 class="wp-block-heading">Slowing smartphone market</h4>
A slowdown in the smartphone market could be a major spoiler for AAC's young comeback. Global smartphone shipments totaled 1.24 billion units last year, up 6.4% from 2023, according to data tracking firm IDC. But fourth-quarter shipments rose by a far smaller 2.4% year-on-year to 332 million units, and IDC expects the market to continue growing at a slower pace this year.
Fierce competition, which has led customers to pit their suppliers against each other in a quest for lower prices, has also made it nearly impossible for AAC to regain the high margins it once enjoyed. The company boasted a gross margin as high as 41.4% at its height back in 2017. But that figure has been nearly halved to just 21.5% in the first half of 2024. UOB Kay Hian forecasts the company's gross margin will stay at current levels for now, predicting figures of 23.1%, 23.7% and 24.5% from 2024 to 2026, respectively. So, a return to fat profits of earlier years looks unlikely anytime soon.
Outside acoustics, AAC has also been trying to get a toehold in the optical business. Revenue from its optical division grew 24.9% to 2.21 billion yuan in the first half of last year, accounting for nearly 20% of the company's total. But optical components have a far worse gross margin than acoustics, at just 4.7%, limiting the profit potential for that part of the business.
<h4 class="wp-block-heading">Overvalued?</h4>
Seeking to branch out beyond smartphones, AAC has been keen to expand its car acoustics business in recent years. It made a major move in that direction with last year's acquisition of Premium Sound Solutions (PSS), which was part of the previously mentioned Acoustics Solutions International B.V. deal. But its status as a relative latecomer to car acoustics will make it difficult for AAC to catch up with more veteran competitors like&nbsp;Sonavox&nbsp;and&nbsp;Harman, as well as&nbsp;Goertek&nbsp;(002241.SZ), which bought Dynaudio.
All this shows there's probably still some room for AAC to keep growing, though it's unlikely to return to its previous glory days anytime soon. After all, the era of breakneck growth in the early days of smartphones looks increasingly like a distant memory. The company's newer businesses certainly won't bring in big profits over the short-term, as it still needs time to build its credibility in those areas.
Accordingly, investors shouldn't be overly optimistic about the potential for more big gains for AAC's stock, especially after its recent run-up. The company's 2024 profit forecast gives it a sizable price-to-earnings (P/E) ratio of about 31 times. That's slightly head of the 28 times for Shenzhen-listed&nbsp;Luxshare&nbsp;(002475.SZ), even though Luxshare has a higher profit and market capitalization and Shenzhen-listed shares generally trade at higher multiples to their Hong Kong counterparts. Against that kind of backdrop, some may even begin to question whether AAC's stock may be overvalued after its yearlong rally.

Asia

Earnings

Equities

AAC Technologies' Big Comeback Already Priced Into Stock?

Piper Sandler analyst Matt O'Brien initiates coverage on Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) with a Overweight rating and announces Price Target of $26.

Initiation

BBNX

Piper Sandler Initiates Coverage On Beta Bionics with Overweight Rating, Announces Price Target of $26

FOXO Technologies Inc.&nbsp;(NYSE American:&nbsp;FOXO)&nbsp;(the "Company or FOXO"), announces that it has executed a non-binding acquisition agreement for two assisted living facilities in Florida.
One facility has 129 units, and the second facility has 137 units. The purchase price for each facility is expected to be $30 million, a portion of which is milestone-based. The parties aim to complete definitive agreements withing 60 days, Closing is expected to occur between 60 and 120 days after completion of definitive agreements and is subject to a number of closing conditions, including satisfactory due diligence and financing.

FOXO

Foxo Technologies Announces Execution Of A Non-Binding Acquisition Agreement For Two Assisted-Living Facilities In Florida For A Total Consideration Of $60M

ImmunoPrecise Antibodies (the "Company" or "IPA") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPA#NASDAQ">IPA</a>), an AI-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of Kamil Isaev to its Board of Directors and Joseph Scheffler as Interim Chief Financial Officer (CFO). Additionally, IPA announces the planned departure of Chris Buyse from the Board of Directors.

Management

ImmunoPrecise Antibodies Announces The Appointment Of Kamil Isaev To Its Board Of Directors And Joseph Scheffler As Interim Chief Financial Officer

Dividends

Steel Dynamics Announces 9% Dividend Increase From $0.46 To $0.50 Per Share For Q1 2025, Payable April 11

Scaled Investment Platform Expands Apollo's Origination Capabilities in Residential and Industrial Real Estate
Bridge Manages $50 Billion of High-Quality AUM in Complementary Sectors Aligned with Apollo's Long-Term Growth Strategy
NEW YORK and SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Apollo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) and Bridge Investment Group Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRDG#NYSE">BRDG</a>) ("Bridge" or the "Company") today announced they have entered into a definitive agreement for Apollo to acquire Bridge in an all-stock transaction with an equity value of approximately $1.5 billion.

Asset Sales

BRDG

Apollo Has Entered Into A Definitive Agreement To Acquire Bridge In An All-Stock Transaction With An Equity Value Of ~$1.5B

reAlpha Tech Corp. ("reAlpha") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRE#NASDAQ">AIRE</a>), a real estate technology company developing and commercializing artificial intelligence ("AI") technologies, today announced the acquisition of GTG Financial, Inc. ("GTG Financial"), a mortgage brokerage company founded by Glenn Groves, a U.S. Marine and industry leader. GTG Financial is licensed to operate in seven U.S. states, including California, which will expand reAlpha's geographic footprint to a total of 28 U.S. states and strengthen its operational capacity.

AIRE

reAlpha Acquires GTG Financial, Inc.; No Financial Terms Disclosed

Celularity Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/celu#NASDAQ">CELU</a>) ("Celularity" or the "Company"), a cellular and regenerative medicine company, today announced that it has entered into a Master Services Collaboration Agreement with BlueSphere Bio, Inc.
Celularity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) ("Celularity" or the "Company"), a cellular and regenerative medicine company, today announced that it has entered into a Master Services Collaboration Agreement with BlueSphere Bio, Inc. (BSB) covering manufacturing activities for certain BSB cell therapy products. This collaboration is the second of its kind for Celularity and demonstrates the Company's ability to leverage its world class cGMP manufacturing infrastructure and deep expertise to attract clients like BSB, who are seeking differentiated alternatives to manufacture their therapeutic products in an ever-changing landscape. This collaboration further evidences the revenue generating potential of Celularity's assets.
The Collaboration Agreement will initially focus on the production of BSB's novel T cell receptor (TCR) T cell therapies using the technical and manufacturing capabilities at Celularity's Florham Park, NJ, cGMP-ready facility. This collaboration will extend to all aspects of cell therapy manufacturing including Chemistry, Manufacturing and Controls (CMC), Quality Assurance and Quality Control. As part of this Collaboration, Celularity will dedicate staff and a small portion of its 37,000 square foot commercial manufacturing footprint. In coordination with&nbsp;Celularity management,&nbsp;BSB and its team will have oversight over production of its second cell therapy product for the treatment of Acute Myelogenous Leukemia (AML) both in the U.S. and abroad.

CELU

Celularity Announces Master Services Collaboration With BlueSphere Bio For Manufacturing BSB Cell Therapy Products, Utilizing Florham Park cGMP Facility; Project Involves 37K Sq Ft Space, Focus On TCR T Cell Therapy For AML

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.1400</td>
<td align="right">0.390</td>
<td align="right">0.76</td>
<td>253.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">91.4468</td>
<td align="right">0.517</td>
<td align="right">0.56</td>
<td>4.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">88.5000</td>
<td align="right">0.430</td>
<td align="right">0.48</td>
<td>336</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">135.4200</td>
<td align="right">0.580</td>
<td align="right">0.43</td>
<td>1.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">80.6200</td>
<td align="right">0.350</td>
<td align="right">0.43</td>
<td>1.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">147.0600</td>
<td align="right">0.630</td>
<td align="right">0.43</td>
<td>2.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">235.8400</td>
<td align="right">0.970</td>
<td align="right">0.41</td>
<td>7.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">219.0300</td>
<td align="right">0.640</td>
<td align="right">0.29</td>
<td>2.6K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">82.3800</td>
<td align="right">0.200</td>
<td align="right">0.24</td>
<td>9.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">42.2900</td>
<td align="right">0.060</td>
<td align="right">0.14</td>
<td>933</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">103.1300</td>
<td align="right">0.110</td>
<td align="right">0.10</td>
<td>282</td>
</tr>
</tbody>
</table>
No loser in today's Pre-market session. 
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> the above sector movers alert assists traders in understanding macro-level trends and market variations. Traders will look for sector movers providing information on sectors that are over- or under-performing, deriving these results into investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For February 24, 2025

<a href="https://www.sec.gov/Archives/edgar/data/1713210/000149315225007977/ex99-1.htm" title="https://www.sec.gov/Archives/edgar/data/1713210/000149315225007977/ex99-1.htm">https://www.sec.gov/Archives/edgar/data/1713210/000149315225007977/ex99-1.htm</a>

Comments

Blue Bird

Blue Bird (BLBD) オプション

Blue Bird (NASDAQ:BLBD) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル